FreeTender
Accepting bidsgrantUnited States

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities

Verify & apply on the official portal →
Published
3 Nov 2026
Closes
16 Nov 2029, 23:59 UTC
Reference
PAR-28-042
Location
United States
Sector
Healthcare & Pharma

At a glance

National Institutes of Health in United States has published a funding call in healthcare & pharma: “Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)”. Submissions close on 16 November 2029, 1109 days from today. Quote reference PAR-28-042 in any correspondence with the buyer. FreeTender has recorded 458 notices from this buyer since 2023, 383 of them currently open. There are 402 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.

Details

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

CFDA number(s): 93.CA1

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 458 notices from National Institutes of Health, going back to May 2023 — 383 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 402 open Healthcare & Pharma tenders in United States. This one closes in 1109 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
Common bidding mistakes to avoid →Writing a winning proposal

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →